Gen-Probe, BioMerieux Pen Three Technology Agreements | GenomeWeb

Gen-Probe, BioMerieux Pen Three Technology Agreements

Oct 07, 2004

NEW YORK, Oct. 7 (GenomeWeb News) - Gen-Probe and BioMerieux have signed three agreements in which Gen-Probe will pay for access to BioMerieux's blood clot-related biomarkers for blood clotting disorders, Gen-Probe will gain negotiation rights for access to the BioMerieux Nuclisens EasyQ platform, and BioMerieux will have access to Gen-Probe's ribosomal RNA markers, said BioMerieux in a statement today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Bit of Uncertainty

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Effect of Sex

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Better Microbes

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

This Week in PNAS

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.